Like many medications intended for use over a period of many years, questions of bisphosphonates' safety have repeatedly arisen and must be addressed anew now that there is a suspected association with atrial fibrillation. The Food and Drug Administration, after conducting a review of the latest data, has issued an Early Communication advising health care providers not to alter their prescribing practices and patients not to discontinue their bisphosphonate medication.